Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to test the hypothesis that intravenous infusion of LY2062430 will slow the decline of AD as compared with placebo, as assessed at 80 weeks after initiation of treatment using a mixed-model repeated-measures (MMRM) analysis of 2 coprimary outcomes, the 11 item Alzheimer?s Disease Assessment Scale?Cognitive subscore (ADAS-Cog11) and the Alzheimer?s Disease Cooperative Study?Activities of Daily Living Inventory (ADCS-ADL). The specific hypothesis is that the change at the end of the treatment phase for LY2062430 will be significantly less than that for placebo.
Critère d'inclusion
- Alzheimer's disease,Enfermedad de Alzheimer